

# Gamal Esmat

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1731711/publications.pdf>

Version: 2024-02-01

166  
papers

4,438  
citations

145106

33  
h-index

150775

59  
g-index

171  
all docs

171  
docs citations

171  
times ranked

5835  
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , 2011, 31, 61-80.	1.9	481
2	Hepatic and Intestinal Schistosomiasis: Review. <i>Journal of Advanced Research</i> , 2013, 4, 445-452.	4.4	161
3	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. <i>New England Journal of Medicine</i> , 2020, 382, 1166-1174.	13.9	160
4	Human Schistosomiasis: Clinical Perspective: Review. <i>Journal of Advanced Research</i> , 2013, 4, 433-444.	4.4	141
5	Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. <i>Journal of General Virology</i> , 2007, 88, 1526-1531.	1.3	121
6	High Seroprevalence of Hepatitis C Infection among Risk Groups in Egypt. <i>American Journal of Tropical Medicine and Hygiene</i> , 1994, 51, 563-567.	0.6	120
7	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	1.8	114
8	Grading of Hepatic Schistosomiasis by the Use of Ultrasonography. <i>American Journal of Tropical Medicine and Hygiene</i> , 1992, 46, 403-408.	0.6	102
9	Role of hepatitis C infection in chronic liver disease in Egypt.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 436-442.	0.6	102
10	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. <i>Gut</i> , 2015, 64, 948-956.	6.1	101
11	The current and future disease burden of chronic hepatitis C virus infection in Egypt. <i>Arab Journal of Gastroenterology</i> , 2014, 15, 45-52.	0.4	88
12	Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. <i>Gut</i> , 2010, 59, 1135-1140.	6.1	87
13	A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. <i>Phytomedicine</i> , 2009, 16, 391-400.	2.3	82
14	Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. <i>Journal of Medical Virology</i> , 2021, 93, 5833-5838.	2.5	79
15	Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1624-1630.	1.4	71
16	MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. <i>Oncology Letters</i> , 2016, 12, 2567-2573.	0.8	66
17	Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 36-44.	3.7	61
18	miR-1275: A single microRNA that targets the three IGF2 mRNA-binding proteins hindering tumor growth in hepatocellular carcinoma. <i>FEBS Letters</i> , 2015, 589, 2257-2265.	1.3	57

#	ARTICLE	IF	CITATIONS
19	Changing Patterns of Acute Viral Hepatitis at a Major Urban Referral Center in Egypt. <i>Clinical Infectious Diseases</i> , 2007, 44, e30-e36.	2.9	51
20	Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic <sc>HCV</sc> genotype <sc>IV</sc> infected patients. <i>Liver International</i> , 2017, 37, 534-541.	1.9	51
21	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. <i>Journal of Hepatology</i> , 2018, 68, 691-698.	1.8	50
22	Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. <i>Journal of Medical Virology</i> , 2009, 81, 1576-1583.	2.5	47
23	Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. <i>Clinical Rheumatology</i> , 2010, 29, 1373-1380.	1.0	47
24	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. <i>Human Immunology</i> , 2016, 77, 667-673.	1.2	44
25	Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1112-1119.	1.9	43
26	HCV in Egypt, prevention, treatment and key barriers to elimination. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 345-350.	2.0	43
27	Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 843-850.	1.4	42
28	Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. <i>The Lancet Global Health</i> , 2014, 2, e541-e549.	2.9	42
29	HCV-related morbidity in a rural community of Egypt. <i>Journal of Medical Virology</i> , 2006, 78, 1185-1189.	2.5	40
30	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. <i>Journal of Advanced Research</i> , 2015, 6, 301-310.	4.4	40
31	Improvement of glycemic state among responders to Sofosbuvir-based treatment regimens: Single center experience. <i>Journal of Medical Virology</i> , 2017, 89, 2181-2187.	2.5	39
32	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 49-54.	0.5	37
33	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 1-11.	1.1	37
34	Safety of direct antiviral agents in the management of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1643-1652.	1.0	36
35	Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. <i>Growth Factors</i> , 2016, 34, 42-50.	0.5	36
36	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virus-Infected Patients in a Country With Limited Resources: The Case of Egypt. <i>Clinical Infectious Diseases</i> , 2014, 58, 1064-1071.	2.9	34

#	ARTICLE	IF	CITATIONS
37	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. <i>Gut</i> , 2019, 68, 721-728.	6.1	34
38	Repressed induction of interferon-related microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. <i>FEBS Open Bio</i> , 2012, 2, 179-186.	1.0	33
39	Serum Î±-Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 797-803.	0.6	33
40	Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. <i>Comparative Hepatology</i> , 2010, 9, 1.	0.9	31
41	Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4. <i>Arab Journal of Gastroenterology</i> , 2015, 16, 50-53.	0.4	31
42	Impact of Toll-like Receptors 2(TLR2) and TLR 4 Gene Variations on HCV Susceptibility, Response to Treatment and Development of Hepatocellular Carcinoma in Cirrhotic HCV Patients. <i>Immunological Investigations</i> , 2020, 49, 462-476.	1.0	30
43	Optimizing treatment for <scp>HCV</scp> genotype 4: PEGÎ±FN alfa 2a vs. PEGÎ±FN alfa 2b; the debate continues. <i>Liver International</i> , 2014, 34, 24-28.	1.9	28
44	Human cytomegalovirus infection inhibits response of chronic hepatitis C virus-infected patients to interferon-based therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 55-62.	1.4	27
45	Strong Hepatitis C Virus (HCV)-specific Cell-mediated Immune Responses in the Absence of Viremia or Antibodies Among Uninfected Siblings of HCV Chronically Infected Children. <i>Journal of Infectious Diseases</i> , 2011, 203, 854-861.	1.9	27
46	Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 773-778.	1.4	27
47	Managing diabetes and liver disease association. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 166-179.	0.4	27
48	Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. <i>Archives of Virology</i> , 2019, 164, 1587-1595.	0.9	27
49	Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. <i>Pediatric Diabetes</i> , 2010, 11, 462-470.	1.2	26
50	Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-7.	0.7	26
51	One step closer to elimination of hepatitis C in Egypt. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 665.	3.7	26
52	How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries. <i>Hepatology</i> , 2015, 62, 31-39.	3.6	25
53	FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. <i>Arab Journal of Gastroenterology</i> , 2016, 17, 78-83.	0.4	25
54	Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 249-255.	0.7	24

#	ARTICLE	IF	CITATIONS
55	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
56	Is <i>Schistosoma mansoni</i> Replacing <i>Schistosoma haematobium</i> in the Fayoum?. <i>American Journal of Tropical Medicine and Hygiene</i> , 1993, 49, 697-700.	0.6	24
57	Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. <i>Liver International</i> , 2012, 32, 449-456.	1.9	22
58	A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2015, 12, 645-650.	1.1	22
59	Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. <i>Liver International</i> , 2020, 40, 797-805.	1.9	22
60	Diabetes Association with Liver Diseases: An Overview for Clinicians. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 274-280.	0.6	22
61	Fibroscan of chronic HCV patients coinfecting with schistosomiasis. <i>Arab Journal of Gastroenterology</i> , 2013, 14, 109-112.	0.4	20
62	Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. <i>Oncology Letters</i> , 2015, 10, 3206-3212.	0.8	20
63	Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. <i>Journal of Infection</i> , 2015, 70, 78-87.	1.7	20
64	An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1265-1272.	1.4	20
65	Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2019, 91, 272-277.	2.5	20
66	Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. <i>Archives of Virology</i> , 2013, 158, 1755-1764.	0.9	19
67	Expression signature of microRNA-155 in hepatitis C virus genotype 4 infection. <i>Biomedical Reports</i> , 2015, 3, 93-97.	0.9	19
68	Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1008-1016.	0.8	19
69	Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. <i>World Journal of Gastroenterology</i> , 2018, 24, 1228-1238.	1.4	19
70	Novel scores combining AFP with noninvasive markers for prediction of liver fibrosis in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2018, 90, 1080-1086.	2.5	18
71	NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferon-Ribavirin Therapy in Egyptian Patients. <i>Journal of Clinical Microbiology</i> , 2012, 50, 3886-3892.	1.8	17
72	Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. <i>Journal of Hepatology</i> , 2018, 68, 53-62.	1.8	17

#	ARTICLE	IF	CITATIONS
73	Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab Journal of Gastroenterology, 2019, 20, 175-179.	0.4	17
74	Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program. Clinical Liver Disease, 2019, 14, 203-206.	1.0	16
75	Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study. PLoS ONE, 2021, 16, e0256203.	1.1	16
76	Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt. Journal of Hepatology, 2016, 64, 1240-1246.	1.8	15
77	Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV. Immunology Letters, 2016, 169, 52-60.	1.1	15
78	Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver International, 2018, 38, 2159-2169.	1.9	15
79	Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver International, 2021, 41, 1494-1497.	1.9	15
80	How to optimize HCV therapy in genotype 4 patients. Liver International, 2013, 33, 41-45.	1.9	14
81	Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surgery and Nutrition, 2016, 5, 209-216.	0.7	14
82	Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Review of Clinical Pharmacology, 2016, 9, 1413-1421.	1.3	13
83	Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opinion on Drug Discovery, 2017, 12, 635-642.	2.5	13
84	Comparing the efficiency of Fib-4, FIB-4, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. Journal of Medical Virology, 2018, 90, 1106-1111.	2.5	13
85	Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review. Journal of Advanced Research, 2019, 17, 43-48.	4.4	13
86	Clinical impact of serum Î±-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2019, 31, 1129-1134.	0.8	13
87	HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection. Environmental Science and Pollution Research, 2020, 27, 33659-33667.	2.7	13
88	Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Review of Anti-Infective Therapy, 2020, 18, 637-642.	2.0	13
89	Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	0.8	13
90	Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients. Translational Research, 2012, 159, 190-196.	2.2	12

#	ARTICLE	IF	CITATIONS
91	Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. <i>Biomedical Reports</i> , 2014, 2, 843-848.	0.9	12
92	Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. <i>Frontiers in Physiology</i> , 2018, 9, 1918.	1.3	12
93	Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. <i>Arab Journal of Gastroenterology</i> , 2019, 20, 198-204.	0.4	12
94	The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. <i>Saudi Journal of Gastroenterology</i> , 2022, 28, 3.	0.5	12
95	Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series. <i>Arab Journal of Gastroenterology</i> , 2017, 18, 39-41.	0.4	10
96	Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. <i>International Immunopharmacology</i> , 2021, 99, 108004.	1.7	10
97	Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 628-633.	0.8	9
98	Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. <i>Archives of Virology</i> , 2017, 162, 3283-3291.	0.9	9
99	Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models. <i>Frontiers in Genetics</i> , 2018, 9, 93.	1.1	9
100	Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. <i>Journal of Infection and Public Health</i> , 2020, 13, 1322-1329.	1.9	9
101	Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 450-456.	0.8	8
102	Accurate Prediction of Response to Interferon-based Therapy in Egyptian Patients with Chronic Hepatitis C Using Machine-learning Approaches. , 2012, , .		8
103	Repressing PU.1 by miR-29a in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. <i>Human Immunology</i> , 2015, 76, 687-694.	1.2	8
104	Extrahepatic manifestations in hepatitis C virus infection. <i>Journal of Advanced Research</i> , 2017, 8, 85-87.	4.4	8
105	DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 693-698.	1.4	8
106	Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 338-346.	0.5	7
107	miR-148a and miR-30a limit HCV-dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models. <i>Journal of Medical Virology</i> , 2017, 89, 653-659.	2.5	7
108	High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1194-1199.	0.8	7

#	ARTICLE	IF	CITATIONS
109	Seroprevalence of HCV among Cairo University students in Egypt. <i>Journal of Medical Virology</i> , 2016, 88, 1384-1387.	2.5	6
110	Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. <i>Acta Tropica</i> , 2017, 176, 283-287.	0.9	6
111	A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ravidasvir. <i>Current Drug Discovery Technologies</i> , 2018, 15, 24-31.	0.6	6
112	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 882-887.	0.8	6
113	Anticancer activity of milk fat rich in conjugated linoleic acid against Ehrlich ascites carcinoma cells in female Swiss albino mice. <i>Veterinary World</i> , 2021, 14, 696-708.	0.7	6
114	Antischistosomal therapy: Current status and recent developments. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 1-3.	0.4	5
115	Quality of life of Egyptian donors after living-related liver transplantation. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 21-24.	0.4	5
116	Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4. <i>Mediators of Inflammation</i> , 2013, 2013, 1-10.	1.4	5
117	Epigenetic harnessing of HCV via modulating the lipid droplet-associated protein, TIP47, in HCV cell models. <i>FEBS Letters</i> , 2015, 589, 2266-2273.	1.3	5
118	Diagnostic accuracy of the $\alpha$ -glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4. <i>Gut</i> , 2016, 65, 1577-1578.	6.1	5
119	Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 81-85.	0.5	5
120	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1009-1016.	1.4	5
121	Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 232-240.	0.7	5
122	Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. <i>Platelets</i> , 2021, 32, 383-390.	1.1	5
123	Management of liver disease patients in different clinical situations during COVID-19 pandemic. <i>Egyptian Liver Journal</i> , 2021, 11, 21.	0.3	5
124	miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 300-305.	0.7	5
125	Study of the enhancing effect of sodium chloride injection on radiofrequency ablation of hepatocellular carcinoma. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 63-67.	0.4	4
126	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2017, 37, 348-353.	0.5	4



#	ARTICLE	IF	CITATIONS
127	After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	4
128	Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience. <i>Journal of Medical Virology</i> , 2019, 91, 668-676.	2.5	4
129	High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 907-914.	1.4	4
130	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-8.	2.0	4
131	Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. <i>Annals of Gastroenterology</i> , 2014, 27, 380-386.	0.4	4
132	Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients. <i>Arab Journal of Gastroenterology</i> , 2017, 18, 210-215.	0.4	3
133	The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 103-110.	1.4	3
134	HCV/HIV coinfecting Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 227-232.	0.7	3
135	Antiretroviral therapy optimisation in the time of COVID-19: Is it really different in North and South Africa?. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1118.	0.3	3
136	Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. <i>Journal of Viral Hepatitis</i> , 2022, 29, 474-486.	1.0	3
137	Tamoxifen downregulates MxA expression by suppressing TLR7 expression in PBMCs of males infected with HCV. <i>Journal of Medical Virology</i> , 2014, 86, 1113-1119.	2.5	2
138	Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. <i>BMC Medical Research Methodology</i> , 2014, 14, 39.	1.4	2
139	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813.	1.3	2
140	Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. <i>High-Throughput</i> , 2017, 6, 15.	4.4	2
141	Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. <i>Infection</i> , 2020, 48, 913-922.	2.3	2
142	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 75-87.	0.4	2
143	Micro-elimination of hepatitis C among people living with HIV in Egypt. <i>Liver International</i> , 2021, 41, 1445-1447.	1.9	2
144	Hepatitis C elimination in Africa: Seizing the moment for hepatitis-C free future. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 249-251.	0.4	2

#	ARTICLE	IF	CITATIONS
145	COVID-19 crisis effect on HIV service delivery in Egypt: Hard times or blessings in disguise?. Southern African Journal of HIV Medicine, 2020, 21, 1170.	0.3	2
146	Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Review of Anti-Infective Therapy, 2022, 20, 789-795.	2.0	2
147	Eliminating hepatitis C from countries with high prevalence: When infrastructure comes first. Indian Journal of Medical Research, 2021, 154, 1.	0.4	2
148	HIV-related stigma and discrimination by healthcare workers in Egypt. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, , .	0.7	2
149	Epstein-Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. Arab Journal of Gastroenterology, 2015, 16, 84-89.	0.4	1
150	Response to Real life Egyptian experience of Efficacy / safety of Simeprevir Sofosbuvir in HCV genotype IV. Liver International, 2017, 37, 766-766.	1.9	1
151	Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes. American Journal of Therapeutics, 2018, 25, e776-e779.	0.5	1
152	Derivation of Egyptian varices prediction (EVP) index: A novel noninvasive index for diagnosing esophageal varices in HCV Patients. Journal of Advanced Research, 2022, 35, 87-97.	4.4	1
153	Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	1
154	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	0.7	1
155	Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment. Gastroenterology Research, 2014, 7, 56-63.	0.4	1
156	Egyptian revalidation of non-invasive parameters for predicting esophageal varices in cirrhotic patients: A retrospective study. Arab Journal of Gastroenterology, 2022, 23, 120-124.	0.4	1
157	Management of Hepatitis C Virus Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status. Current Treatment Options in Infectious Diseases, 2016, 8, 368-378.	0.8	0
158	OUP accepted manuscript. Journal of Public Health, 2021, , .	1.0	0
159	Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals. Arab Journal of Gastroenterology, 2021, 22, 158-163.	0.4	0
160	HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt. Experimental and Clinical Transplantation, 2012, 10, 136-140.	0.2	0
161	Parasitic Liver Disease. , 2018, , 568-578.e4.		0
162	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	0.7	0

#	ARTICLE	IF	CITATIONS
163	HCV Infection Amplified Th2 Bias and Th17 Responses In Schistosoma-Infected Patients. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2016, 23, 87-96.	0.1	0
164	IL-17 Induced The Recruitment and Functional Activity of Granulocytes Isolated from Patients Coinfected with Schistosoma mansoni and Hepatitis C Virus. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2017, 24, 9-20.	0.1	0
165	Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status. American Journal of Therapeutics, 2024, 31, e72-e81.	0.5	0
166	The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1365-1372.	0.5	0